Amperozide

DB08927

small molecule experimental

Deskripsi

Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication. Alternatively, amperozide's main use lies in veterinary medicine, where it is typically employed to minimize aggression and stress in intensively farmed pigs.

Struktur Molekul 2D

Berat 401.4927
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

729 Data
Buprenorphine Amperozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Hydrocodone Amperozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Magnesium sulfate The therapeutic efficacy of Amperozide can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Amperozide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Mirtazapine Amperozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Orphenadrine Amperozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Amperozide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Pramipexole Amperozide may increase the sedative activities of Pramipexole.
Ropinirole Amperozide may increase the sedative activities of Ropinirole.
Rotigotine Amperozide may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Amperozide.
Sodium oxybate Amperozide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Amperozide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Thalidomide Amperozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Amperozide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Amperozide may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Amperozide is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Amperozide is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amperozide.
Metyrosine Amperozide may increase the sedative activities of Metyrosine.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Amperozide.
Sulpiride Amperozide may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Amperozide.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Amperozide.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Amperozide.
Mequitazine Amperozide may increase the arrhythmogenic activities of Mequitazine.
Tetrabenazine The risk or severity of adverse effects can be increased when Amperozide is combined with Tetrabenazine.
Deutetrabenazine The risk or severity of adverse effects can be increased when Amperozide is combined with Deutetrabenazine.
Dicoumarol The risk or severity of adverse effects can be increased when Amperozide is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Amperozide is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Amperozide is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Amperozide is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Amperozide is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Amperozide is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Amperozide is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Amperozide is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Amperozide is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Amperozide is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Amperozide is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Amperozide is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Amperozide is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Amperozide is combined with (S)-Warfarin.
Ethanol Amperozide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Amperozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.
Zimelidine The risk or severity of adverse effects can be increased when Amperozide is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Amperozide is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Amperozide is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Amperozide is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Amperozide is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Amperozide is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Amperozide is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Amperozide is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Amperozide is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Amperozide is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Amperozide is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Amperozide is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Amperozide is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Amperozide is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Amperozide.
Indalpine The risk or severity of adverse effects can be increased when Amperozide is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Amperozide is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Amperozide is combined with Alaproclate.
Zopiclone The risk or severity of adverse effects can be increased when Amperozide is combined with Zopiclone.
Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Amperozide.
Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Amperozide.
Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amperozide.
Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amperozide.
Meperidine The risk or severity of adverse effects can be increased when Meperidine is combined with Amperozide.
Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amperozide.
Mazindol The risk or severity of adverse effects can be increased when Mazindol is combined with Amperozide.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Amperozide.
Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Amperozide.
Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Amperozide.
Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Amperozide.
Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Amperozide.
Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Amperozide.
Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Amperozide.
Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Amperozide.
Ergoloid mesylate The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amperozide.
Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Amperozide.
Chlorpheniramine The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Amperozide.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Amperozide.
Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Amperozide.
Ergometrine The risk or severity of adverse effects can be increased when Ergometrine is combined with Amperozide.
Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Amperozide.
Lorcaserin The risk or severity of adverse effects can be increased when Lorcaserin is combined with Amperozide.
Etoperidone The risk or severity of adverse effects can be increased when Etoperidone is combined with Amperozide.
Lorpiprazole The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Amperozide.
Amphetamine Amperozide may decrease the stimulatory activities of Amphetamine.
Phentermine Amperozide may decrease the stimulatory activities of Phentermine.
Pseudoephedrine Amperozide may decrease the stimulatory activities of Pseudoephedrine.

Target Protein

5-hydroxytryptamine receptor 2A HTR2A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2154737
    Svartengren J, Simonsson P: Receptor binding properties of amperozide. Pharmacol Toxicol. 1990;66 Suppl 1:8-11.
  • PMID: 1388121
    Meltzer HY, Zhang Y, Stockmeier CA: Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Eur J Pharmacol. 1992 May 27;216(1):67-71.
  • PMID: 1979998
    Eriksson E: Amperozide, a putative anti-psychotic drug: uptake inhibition and release of dopamine in vitro in the rat brain. Life Sci. 1990;47(23):2111-7.
  • PMID: 1403783
    Yamamoto BK, Meltzer HY: The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo. J Pharmacol Exp Ther. 1992 Oct;263(1):180-5.
  • PMID: 2304893
    Grenhoff J, Tung CS, Ugedo L, Svensson TH: Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol. 1990;66 Suppl 1:29-33.
  • PMID: 1924636
    Axelsson R, Nilsson A, Christensson E, Bjork A: Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychopharmacology (Berl). 1991;104(3):287-92.
  • PMID: 2224491
    Kyriakis SC, Martinsson K, Olsson NG, Bjork A: Thin sow syndrome (TSS): the effect of amperozide. Br Vet J. 1990 Sep-Oct;146(5):463-7.
  • PMID: 1788479
    Kyriakis SC, Olsson NG, Martinsson K, Bjork AK: Observations on the action of amperozide: are there social influences on sow-litter productivity? Res Vet Sci. 1991 Sep;51(2):169-73.
Menampilkan 8 dari 9 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul